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Summary
Purpose: To report on the ﬁrst multicenter Italian experience with zonisamide as an add-on
drug for refractory generalised or partial epilepsy in children, adolescents and young adults.
Methods: The patients were enrolled in a prospective, add-on, open-label treatment study from
eight Italian centres for children and adolescent epilepsy care. Eighty-two young patients (45
males, 37 females), aged between 3 and 34 years (mean 13.1 years), all affected by partial (47)
or generalised (35) refractory epilepsy, were enrolled in the study.
ZNS was added to the baseline therapy at a starting dose of 1mg/kg/day twice daily. This
dose was increased by 2mg/kg every 1—2 weeks over a period of up 3 months, according to the
patient’s response and tolerability, up to a maximum dose of 12mg/kg. ZNS was given at the
mean daily dose of 5.7/mg/kg/24 h (range 1—12mg/kg).
Results: After a mean follow-up period of 11.9 months (range 2—64 months), 9 patients (10.9%)
were seizure-free. The number of seizures decreased by 50—99% in 31 cases (37.8%), by 25—49%
in 5 cases (6.1%), remained the same in 29 cases (35.4%) and increased in 8 cases (9.7%).
∗ Corresponding author. Tel.: +39 081 5666695; fax: +39 081 5666694.
E-mail address: giangennaro.coppola@unina2.it (G. Coppola).
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After 15 months of follow-up, 61 patients (74.4%) were still taking ZNS, while the remaining 21
(25.6%) had stopped. Twenty-two patients (26.8%) reported adverse effects while taking ZNS.
They generally appeared during the ﬁrst weeks of treatment, and were mild to moderate. The
most frequent adverse effects were irritability and a reduced appetite.
Conclusion: ZNS effectively reduced seizure frequency in this pediatric population with both
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ized epilepsy (including 2 with Lennox—Gastaut syndrome, 3
with myoclonic—astatic syndrome, 6 with severe myoclonic
epilepsy in infancy, and 2 with continuous spike and wavepartial and generalised crypt
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Introduction
The novel antiepileptic drug zonisamide (ZNS) is char-
acterised by a broad range of pharmacological effects
associated with multiple mechanisms of action. These
include a voltage-sensitive sodium and T-type calcium chan-
nel blockade, a reduction in glutamate-mediated synaptic
excitation and enhanced inhibitory effects mediated by
gamma-aminobutyrric acid (Biton, 2004).
Zonisamide has recently been approved in Europe for the
adjunctive treatment of refractory partial seizures in adults.
It has been available in Japan since, 1989, with studies there
having established that ZNS is effective and safe for use in
children (Ohtahara, 2006). Information from other countries
concerning its use in pediatric patients is still somewhat
limited. There are, however, a growing number of studies
reporting the clinical efﬁcacy of ZNS, both as add-on ther-
apy (Kim et al., 2005; Mandelbaum et al., 2005; Santos and
Brotherton, 2005; Ohtahara, 2006; Kluger et al., 2008) and
as monotherapy (Miura, 2004; Seki et al., 2004; Kim et al.,
2005; Kothare et al., 2006) in pediatric generalised and par-
tial seizures.
The aim of this paper is to report on the ﬁrst multicen-
tre Italian experience with ZNS as an add-on drug for the
treatment of refractory generalised and partial epilepsy in
children, adolescents and young adults.
Methods
Patients were recruited in a prospective add-on, open-label treat-
ment study from eight Italian centres for pediatric and adolescent
epilepsy care. The patients were selected according to the follow-
ing criteria: (1) age one year and over; (2) partial or generalised
epileptic seizures refractory to at least three previous antiepilep-
tic drugs (AEDs), alone or in combination; (3) more than 1 seizure
per month in the last 6 months; (4) use of at least one other AED,
but no more than two, at baseline; (5) informed consent from par-
ents/caregivers, who had to be able to administer the study drug
and record seizures in a diary. Moreover, female patients of child-
bearing age were required not to be pregnant and to be using an
adequate form of contraception.
Exclusion criteria included progressive neurological or systemic
disease. Patients with signiﬁcantly abnormal liver, kidney and blood
laboratory values were also excluded, as were those who were con-
sidered to be unlikely to comply with the study requirements.
Besides enrolling ZNS-naïve subjects, study sites that had pre-
viously started patients on ZNS had the option of enrolling patients
who had completed at least 6 months of maintenance treatment
and met the study inclusion and exclusion criteria.Pseudo-seizures were excluded by means of video-EEG record-
ings and/or long-term monitoring EEGs. CT and MRI were performed
in all cases. The number of seizures was recorded by parents and
caregivers at home and at school. Seizure frequency, type and dura-
tion were recorded in an epilepsy diary to be kept and reviewed at
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tptomatic refractory epilepsy. Its overall tolerability was good.
erved.
ach follow-up visit. Seizures were classiﬁed according to the Inter-
ational League against Epilepsy (ILAE) classiﬁcation of epileptic
eizures (ILAE Commission, 1981), while severe myoclonic epilepsy
n infancy was diagnosed according to Dravet’s criteria (Dravet et
l., 1984).
There was an initial observation period of 6 months (baseline),
uring which antiepileptic treatment was generally left unchanged
nless particular reasons arose, such as the occurrence of status
pilepticus. If seizures occurred daily, the observation period could
e shortened to 3 months.
After the observation period, ZNS was added to the baseline
herapy at the starting dose of 1mg/kg/day twice daily. The dose
as increased by 2mg/kg every 1—2 weeks over a period of up to
months. The dose was adjusted at the investigator’s discretion
ccording to the patient’s response and tolerability, up to a maxi-
um dose of 12mg/kg. Patients procured zonisamide on their own
uring the trial period. Concomitant therapy was generally not mod-
ﬁed at any time during the study. If any adverse event occurred,
he titration phase could be extended according to the patient’s
linical conditions. Rescue drugs were allowed whenever neces-
ary. EEG, adverse effects and blood levels of concomitant AEDs
ere monitored in all patients. Patients were followed on a weekly
asis during the titration period, either by means of visits to the
linic or by telephone. Patients subsequently visited the clinic at 3-
onth intervals during the maintenance treatment, with a monthly
ollow-up by telephone between visits to the clinic whenever nec-
ssary. Blood chemistry and liver and kidney function were carefully
ssessed at each time interval. Parents/caregivers were informed
f the potential clinical adverse effects to refer to the clinician.
The response to treatment, in relation to the baseline, was rated
s follows: (i) seizure control (100% seizure remission); (ii) 50—99%
ecrease in number of seizures; (iii) 25—49% decrease in number of
eizures; (iv) unchanged when the seizure rate remained the same;
v) worsened when the seizure rate increased.
The Institutional Review Board from each epilepsy unit approved
he study; no support was received from pharmaceutical companies.
The statistical analysis was performed by means of a two-tailed
ilcoxon Rank test for non-parametric data and the 2 test.
esults
ighty-two young patients (45 males, 37 females), aged
etween 3 and 34 years (<6 years: 20.7%; 7—12 years:
5.4%; 13—18 years: 23.2%; >19 years: 20.7%: mean
ge 13.1 years), all affected by refractory epilepsy,
ere enrolled in the study. Patient diagnoses were as
ollows: symptomatic (28) and cryptogenic (19) partial
pilepsy; symptomatic (19) and cryptogenic (16) general-tatus during slow sleep. The mean duration of epilepsy
as 10.2 years (range 1—31 years). Seizure types, which
ere often combined, were as follows: complex par-
ial (24), secondarily generalised partial seizures (21),
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Table 1 Response to treatment with zonisamide according to epilepsy type.
Seizure decrease (%) Partial epilepsy (n = 47)n Generalised epilepsy (n = 35)n
Cryptogenic Symptomatic Cryptogenic Symptomatic
N % N % N % N %
100 7n 36.8 0n 2n 12.5 0n
50—99 7n 36.8 13n 46.4 5n 31.2 6n 31.6
25—49 0 1 3.6 2 12.5 2 10.5
Unchanged 3 15.8 11 39.3 7 43.8 8 42.1
Increased 2 10.5 3 10.7 0 3 15.8
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ZTotal 19 100.0 28
n 2 = .780, p = .377.
onic (19), epileptic spasms (10), tonic-clonic (10), atonic
8), myoclonic (7).
Seizure frequency at baseline was:≥1/day in 49 patients,
—15/month in 19 patients, and 1—4/month in 14 patients.
he mean total number of seizures per month at baseline
as 97.0 (range 4—900).
CT/MRI imaging scans disclosed abnormal ﬁndings in 47
atients (57.3%): brain atrophy (16), gliosis (14), migra-
ion disorders (12), tuberous sclerosis (2), poroencephaly
1), tetraventricular hydrocephalus (1), dysembrioplas-
ic neuroepithelioma (1). This last case was included
ecause serial MRI scans ruled out growth of the
umor.
Developmental psychomotor and mental level was nor-
al in 14 patients (17%); a mild delay was found in 14 (17%),
moderate delay in 9 (10.9%), and severe/profound delay
n 45 patients (54.9%).
The neurological examination was abnormal in 39
atients (47.6%): 21 patients had spastic tetrapare-
is, 3 generalised hypotonia, 3 diplegia, 4 hemiparesis,
double hemiparesis, 1 hypotonic syndrome and 5
taxia.
Five patients were taking one other AED concomitantly
PB, OXC, VGB, CBZ, NZP), 77 were taking two. The following
EDs were taken in various combinations with ZNS: VPA (32),
DZ (29), CBZ (17), PB(16), LEV (13), LTG (11), TPM (13), PHT
8), OXC (8), FBM (5), VGB (5), AZM (5), GBP (2), PGB (1),
TP (1), KD (1).
ZNS was given at a mean daily dose of 5.7/mg/kg/24 h
range 1—12mg/kg/day).
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igure 1 Percentages of patients according to seizure type who ex
NS was added to their baseline therapy.16 100.0 19 100.0
fﬁcacy
fter a mean follow-up period of 11.9 months (range 2—64
onths), 9 patients were seizure-free (10.9%; mean follow-
p 11.2 months). A 50—99% reduction in seizure frequency
as found in 31 cases (37.8%), a 25—49% in 5 cases (6.1%),
hile seizure frequency remained unchanged in 29 patients
35.4%) and increased in 8 patients (9.7%) (Table 1).
Overall, ZNS was more effective (though not signiﬁcantly)
n partial than in generalised epilepsy (57.4% vs 37.1%,
espectively; p = .377), and, though to a lesser extent, in
oth partial (p = .478) and generalised (p = .860) cryptogenic
pilepsy.
As for the epilepsy type, 4 of the 6 patients with Dravet
yndrome did not respond, while the remaining 2 had a
50% reduction in the number of tonic-clonic and myoclonic
eizures.
Two of the three patients with myoclonic—astatic
pilepsy had a 50% reduction in the number of seizures,
hile two patients with Lennox—Gastaut syndrome did not
mprove. Two other children, aged 9 and 11 years, with a
ontinuous spike-and-wave status during slow sleep EEG pat-
ern and monthly seizures, were seizure-free after 6 and 3
onths. EEG showed a signiﬁcant decrease in the spike-and-
ave index during slow sleep stages in one, while it was
nchanged in the other.
As for seizure type, ZNS was most effective (i.e.≥ 50%
eduction in seizure frequency) in the treatment of par-
ial seizures with or without secondary generalisation, tonic
eizures and epileptic spasms (Fig. 1).
perienced a 50% or greater reduction in seizure frequency when
Zonisamide in children and young adults with refractory epilepsy 115
Figure 2 Response to ZNS therapy according to seizure
Figure 4 Kaplan—Meyer survival curve for 15-month treat-
ment with ZNS showing the number of patients still being
treated.
Table 2 All treatment-emergent adverse effects during
the follow-up period.
(No. of patients)
Body as a whole Weakness, 5
Weight gain, 1
Adenomegaly,1
Digestive Transient vomiting, 1
Decreased appetite, 3
Abdominal pain, 1
Nervous system Irritability, 9
Drowsiness, 2
Insomnia, 2
Inattention, 1
Cephalalgia, 1
Choreoathetosis,1
Skin Rash, 1frequency during baseline period. (For interpretation of the ref-
erences to color in this ﬁgure legend, the reader is referred to
the web version of the article.)
No signiﬁcant relationship was found between respon-
ders and non-responders in age at exposure to ZNS, duration
of epilepsy, aetiology, sex and baseline therapy (p > 0.5;
Wilcoxon Rank Sum test).
Seizure frequency did not increase when ZNS was added
to therapy in patients with a lower baseline seizure fre-
quency (Fig. 2).
Seizure frequency increased following addition of ZNS
in 8 patients (9.7%). Fig. 3 shows that the increase in
seizure frequency following the addition of ZNS was compa-
rable in the different seizure types. An increase in seizure
frequency generally occurred during the ﬁrst weeks of treat-
ment at daily doses of 0.5—2mg/kg. In two patients, seizures
became very frequent but promptly stopped after ZNS with-
drawal. The mean age in this group of 8 patients was 13.7
years and the seizure frequency was ≥1/day at baseline in
75% of patients.
After 15 months of follow-up, 61 pts (74.4%) were still
taking ZNS, while the remaining 21 (25.6%) had stopped tak-
ing the drug owing to its lack of efﬁcacy in reducing seizure
frequency, even at the maximum doses used (see Fig. 4,
Kaplan—Meyer survival curve).
The mean total number of seizures per month during
follow-up was 71.4 (range 0.2—660).
TolerabilityTwenty-two patients (26.8%) reported adverse effects while
taking ZNS (Table 2). Adverse effects generally appeared
during the ﬁrst weeks of treatment and were mild to moder-
ate in severity. Only one patient stopped treatment because
o
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t
w
Figure 3 Percentages of patients who experienced a 25% or great
treatment regimen.Special senses Conjunctivitis, 1f adverse effects: this patient developed a skin rash ten
ays after starting ZNS therapy. ZNS was suspended and
ried again, but when the skin rash reappeared, the drug
as deﬁnitively tapered off.
er increase in seizure frequency when ZNS was added to their
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The most frequent adverse effects, which tended to be
NS-related (e.g. irritability and drowsiness), were gener-
lly eliminated by reducing the daily dosage of ZNS or by
lowing down the drug titration.
All the patients’ laboratory test values were normal.
iscussion
n this study, ZNS as add-on therapy signiﬁcantly reduced
eizure frequency in approximately half of our patients who
ad partial or generalised epilepsy that had proved resistant
o at least three previous antiepileptic drugs.
Few patients (10.9%), all of whom were in the crypto-
enic group, became seizure-free. In addition, ZNS proved
o be somewhat more effective in the treatment of partial
eizures.
The overall response to ZNS observed in our study is in
eeping with that reported in Japanese studies and the few
mall-scale studies conducted to date in Europe and the US
n pediatric populations with both partial and generalised
reatment-resistant seizures (38—58% by Kim et al., 2005;
andelbaum et al., 2005; Santos and Brotherton, 2005;
inuma and Haginoya, 2004; Ohtahara, 2006; Kluger et al.,
008). The number of seizure-free patients (10.9%) in our
eries was somewhat lower than that in other studies (16%
nd 25% by Santos and Brotherton (2005), and by Kim et al.
2005), respectively), though this may be ascribed to the
evere refractoriness of our patients.
Worthy of note is the good response to ZNS of drug-
esistant epileptic spasms, which is in keeping with ﬁndings
eported by Lotze and Wilfong (2004). Interestingly, ZNS was
o some extent effective in focal-onset tonic seizures as
ell.
The effect of ZNS was poor in most of the children
n our series with Dravet syndrome and myoclonic—astatic
pilepsy, as well as in the two patients with Lennox—Gastaut
yndrome. Although no conclusions can be drawn from
his ﬁnding owing to the small number of patients with
hese speciﬁc syndromes, it is noteworthy that You et al.
2007) reported 100% seizure control in 4.8% and a >50%
eizure reduction in a further 46.8% of 62 children with
ennox—Gastaut syndrome treated with ZNS as long-term
djunctive therapy.
The data yielded by our study regarding seizure wors-
ning are in keeping with those by Kim et al. (2005) (9%
nd 14.5%, respectively). An increase in seizure frequency
ccurred above all in the ﬁrst weeks of treatment, often
uring the dose-escalation phase, with no relationship with
eizure type being found. If an increase in seizure frequency
id occur, values promptly returned to those at baseline
fter ZNS withdrawal; the explanation for this increase is
hus more likely to be ascribable to a direct role of ZNS as
pposed to a natural ﬂuctuation in seizure frequency.The retention rate observed in our series is consistent
ith that reported by Kluger et al. (2008) (60% and 41.7%,
espectively), though somewhat higher. This high retention
ate may be attributed not so much to the efﬁcacy of ZNS
s to its overall good tolerability.
YG. Coppola et al.
Most of the adverse effects, including somnolence, ner-
ousness, and decreased appetite, were related to the
entral nervous system. On the whole, these adverse effects
ere mild to moderate, and mostly occurred during titration
osing and resolved in maintenance dosing. No serious side
ffects were observed.
In conclusion, in our experience ZNS reduced seizure
requency in young patients with partial and generalised
rypto/symptomatic refractory epilepsy. Moreover, ZNS was
enerally well tolerated in this population study. Further
tudies are warranted to gain a better understanding of the
fﬁcacy of ZNS both in the long term and in the treatment
f well-deﬁned epileptic syndromes.
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